ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
[
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial Comment on [International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProstate-specific membrane antigen positron emission tomography (PSMA-PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on
methodsWe retrospectively analyzed 129 patients with prostate cancer who developed BCR after definitive local therapy and underwent [
resultsPSMA-PET identified recurrent lesions in 83% (n = 107), including local recurrence in 40% (n = 51), lymph node metastasis in 43% (n = 55), and bone metastasis in 26% (n = 33); sites were not mutually exclusive. Metastatic lesions were detectable even at low prostate-specific antigen (PSA) levels (≤ 1.0 ng/mL). In multivariate analysis, Grade Group ≥ 4 was independently associated with metastatic disease (odds ratio [OR], 2.65; 95% confidence interval [CI], 1.06-6.77), whereas a PSA doubling time ≥ 8.7 months was independently associated with a lower likelihood of metastasis (OR, 0.12; 95% CI, 0.05-0.27). Among 55 patients who underwent lesion-directed therapy, PSA declines ≥ 90% were observed in 60% of cases.
conclusionsIn this Japanese cohort with BCR, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.